Publications by authors named "R T Streeper"
Growth differentiation factor 15 (GDF15) is a secreted protein that regulates food intake, body weight and stress responses in pre-clinical models. The physiological function of GDF15 in humans remains unclear. Pharmacologically, GDF15 agonism in humans causes nausea without accompanying weight loss, and GDF15 antagonism is being tested in clinical trials to treat cachexia and anorexia.
View Article and Find Full Text PDFBackground: Growth Differentiation Factor 15 (GDF15), a divergent member of the TGF-β superfamily, signals via the hindbrain glial-derived neurotrophic factor receptor alpha-like and rearranged during transfection receptor co-receptor (GFRAL-RET) complex. In nonclinical species, GDF15 is a potent anorexigen leading to substantial weight loss. MBL949 is a half-life extended recombinant human GDF15 dimer.
View Article and Find Full Text PDFInsulin resistance (IR), accompanied by an impaired cellular glucose uptake, characterizes diverse pathologies that include, but are not limited to, metabolic disease, prediabetes and type 2 diabetes. Chronic inflammation associated with deranged cellular signaling is thought to contribute to IR. The key molecular players in IR are plasma membrane proteins, including the insulin receptor and glucose transporter 4.
View Article and Find Full Text PDFArticle Synopsis
- Mycobacterium ulcerans causes Buruli ulcer (BU), leading to skin lesions and immunosuppression due to the virulence factor mycolactone, making early detection and treatment crucial.
- Researchers tested diethyl azelate (DEA) as a potential topical therapy, finding it effective in counteracting the immunosuppressive effects of M. ulcerans in both lab and animal models.
- DEA not only reduced skin lesions and accelerated healing but also preserved immune function, suggesting its promise as a novel treatment for BU and potentially other mycobacterial infections.